Featured News
-
Laboratory Market Stakeholders Call for Suspension of Draft PAMA Rates; Urge CMS to Take Immediate Action to Address Flawed Data Collection and Methodology
ACLA, NILA, AdvaMedDx and POCTA Issue Joint Release Echoing Stakeholder Letter to Administrator Verma WASHINGTON, D.C. – Leading laboratory stakeholders in a joint letter to Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma today called on the agency to take immediate action to address the significant deficiencies in its process to establish new clinical laboratory payment rates. CMS recently issued drastically low draftContinue Reading »... -
ACLA Unveils New Economic Analysis that Underscores Clinical Laboratory Industry’s Contribution to National, State, Local Jobs and Tax Base
Proposed Medicare Cuts to Clinical Lab Services May Cause Lab Closures, Job Losses, and Reduce Patient Access (Washington, D.C.) – The American Clinical Laboratory Association (ACLA) announced a new analysis today that shows clinical laboratories contribute $100 billion in overall economic output to the US economy. ACLA cautioned that proposed Medicare cuts to lab tests by the Centers for Medicare and Medicaid Services (CMS)Continue Reading »... -
ACLA Expresses Serious Concerns with Proposed PAMA Medicare Payment Rates for Clinical Laboratory Tests; Renews Call for Delay and Reform
Draft rates demonstrate failure by CMS to follow Congressional intent, consider full laboratory market in setting rates (Washington, D.C.) – The American Clinical Laboratory Association (ACLA) president, Julie Khani, issued the following statement today in response to the Centers for Medicare and Medicaid Services (CMS) publication of proposed CY2018 Medicare reimbursement rates for clinical laboratory tests under the Protecting Access to Medicare Act (PAMA):Continue Reading »... -
ACLA Names Sharon West as Vice President, Legal & Regulatory Affairs
Veteran health care leader brings laboratory, legal experience to ACLA WASHINGTON, D.C. – The American Clinical Laboratory Association (ACLA) announced that Sharon West joins the association today as vice president of legal and regulatory affairs, where she will represent the nation’s leading clinical laboratories on policy matters impacting the industry. “I am pleased to welcome Sharon to the ACLA team,” said Julie Khani, presidentContinue Reading »... -
ACLA writes CMS Administrator Verma, urging delay and fix to PAMA
... -
ACLA Letter on Medicare Program to Ways and Means Health Subcommittee
... -
ACLA Praises Gottlieb Confirmation as FDA Commissioner
Clinical Laboratory Community Commends New Commissioner For Both His Medical and Government Experience, Support for Scientific Innovation (Washington, D.C.) – The Senate confirmation today of Scott Gottlieb, M.D. as Commissioner of the Food and Drug Administration (FDA), drew praise from the American Clinical Laboratory Association (ACLA), the nation’s leading organization representing clinical laboratories. Commending Dr. Gottlieb for his experience in both the clinical andContinue Reading »... -
ACLA Comments on Bucshon-DeGette Discussion Draft Impacting the Regulation of Clinical Laboratory Diagnostics
(Washington, D.C.) – Today, the American Clinical Laboratory Association (ACLA) submitted comments in response to a discussion draft, the Diagnostic Accuracy and Innovation Act (DAIA), recently released by Representatives Larry Bucshon, M.D. (R-IN) and Diana DeGette (D-CO). ACLA’s comments reiterate the association’s continued support of comprehensive statutory reform to create a distinct framework for clinical laboratory diagnostics that advances innovation and protects patients, includingContinue Reading »... -
ACLA Comments on March 21, 2017 Discussion Draft of the Diagnostic Accuracy and Innovation Act
... -
ACLA Commends CMS’ Decision to Exercise Enforcement Discretion for Reporting Applicable Information Under PAMA
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) today lauded the decision by the Centers for Medicare and Medicaid Services (CMS) to exercise enforcement discretion until May 30, 2017 for laboratories reporting private payor pricing data as required by the Protecting Access to Medicare Act (PAMA). “ACLA appreciates the decision by CMS to exercise enforcement discretion until May 30, 2017,” said Julie Khani,Continue Reading »...
